Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun’s Tildrakizumab Shines In Pivotal Psoriasis Trials

Executive Summary

Sun Pharmaceutical, the world’s fifth-largest specialty generic company, has reported positive results from two pivotal Phase III clinical trials for its psoriasis candidate tildrakizumab, showing that the targeted biologic therapy delivers “significantly improved” skin clearance. While it will face rising competition, some analysts are predicting strong sales

You may also be interested in...



10 First Approvals To Look Out For In 2018

Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.

Keeping Track: Immunology In Focus As US FDA Approves Kevzara, New Breakthrough Actemra Use; J&J, Sun Advance Psoriasis Candidates

The latest immunology drug development news and highlights from our FDA Performance Tracker.

Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?

Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel